Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Completed · Phase 3 · NCT03754790
Conditions: Hemophilia
At a glance
- Research payments reported, 2025
- $95,652
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 281
About the trial
- Sponsor
- Genzyme, a Sanofi Company
- Tested
- Fitusiran (drug)
- Dates
- Started 2019-01-09; completion 2026-09-14
- Results posted
- Not yet
Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: * To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of: * Bleeding episodes * Spontaneous bleeding episodes * Joint bleeding episodes * To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $95,652 in research payments for this study in 2025 (17 payments).
Products named: Qfitlia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Guy A. Young, M.D. Pediatric Hematology & Oncology · Los Angeles, CA
- Erin M. Cockrell, D.O. Pediatric Hematology & Oncology · Tampa, FL
- Julian J. Zorrilla, D.O. Hospitalist · Jacksonville, FL
- Lisa Boggio, MD Hematology & Oncology · Chicago, IL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.